Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced HIV-1 Infected Subjects, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV.

Next Previous
Trial Profile

A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced HIV-1 Infected Subjects, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darunavir (Primary) ; Enfuvirtide; HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms POWER-1

Most Recent Events

  • 20 Feb 2026 According to the Praxis Precision Medicines media release , The POWER1 Phase 3 study for FOS completed enrollment and exceeded its original target; topline results are expected in the second quarter of 2026.
  • 17 Dec 2009 Patient numbers amended from 318 to 334 as reported by ClinicalTrials.gov.
  • 01 Nov 2009 Pooled 96-week results from the POWER-1, -2, AND -3 trials were published in Antiviral Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top